The market has already priced comparable drugs in the billions: oncology exit deals prove that a unique clinical-stage mechanism is worth a fortune. With out-licensing potential above $1B and a modeled IRR of 35–60%, the opportunity speaks the language of numbers.

Exit Comparables

$1.1B

Forma → Novo Nordisk (2023)

$2.3B

Trillium → Pfizer (2021)

$1.3B

Blueprint → BMS (2023)

35–60%

Modeled IRR

$1B+

Out-licensing potential

Q4 2027

Primary BD trigger

7 yrs

FDA exclusivity

2005

Founded

Join the Opportunity

Contact Bridges B2B to arrange a call, investor materials and an NDA.

BRIDGES B2B